Celgene Corp (NASDAQ:CELG) Q4 2017 Sentiment Change, Now at 0.83

May 17, 2018 - By Alice Reed

Celgene Corporation (NASDAQ:CELG) Corporate Logo

“Big money” Positions

In Q4 2017 Celgene Corp (NASDAQ:CELG) big money sentiment decreased to 0.83, SEC.gov filings reveal. That’s down -0.34, from 2017Q3’s 1.17. 529 investment managers increased and started new positions, while 634 sold and decreased stakes in Celgene Corp so the sentiment fall. These funds own 561.38 million shares, that’s down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 decreased from 119 to 38 for a decrease of 81. 156 Investors Sold All; 478 Reduced Holdings; 411 increased holdings while 118 investment managers bought holdings.

Most Celgene Corp Shareholders

As of Q4 2017 Birchview Capital Lp has 45.52% invested in Celgene Corp. As of Q4 2017, 2.11 million shares of Celgene Corp are owned by Oaktop Capital Management Ii L.P.. Selkirk Management Llc reported 260,000 shares. Bb Biotech Ag revealed 3.42 million shares position in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd holds 315,906 shares or 8.7% of their stock exposure.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is worth $59.09 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.22.35 is the P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

CELG hit $81.36 during the last trading session after $0.62 change.Celgene Corporation has volume of 6.04M shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. The stock underperformed the S&P 500 by 42.83%.

On July, 26. Investors expect Celgene Corporation (NASDAQ:CELG) to announce its quarterly earnings, according to Zacks. The EPS diference is $0.19 or 11.31 % up from last years number. Previous year: $1.68; Analysts forcast: $1.87. The profit will be $1.36 billion for CELG if $1.87 EPS becomes true. 16.15 % EPS growth is what analysts predict. $1.61 EPS was published for previous quarter.

Brave Asset Mgmt stated it has 2.14% in Celgene Corporation (NASDAQ:CELG). Segall Bryant & Hamill Ltd Liability owns 29,228 shs for 0.07% of their capital. South Texas Money Mngmt Ltd invested 0.01% in Celgene Corporation (NASDAQ:CELG). Highbridge Mngmt Ltd reported 122,053 shs. Tanaka Cap Mgmt owns 7,087 shs. Taylor Asset, Ontario – Canada-based fund reported 162,200 shs. Healthcor Lp reported 1.73M shs. Moreover, Fuller Thaler Asset has 0.01% invested in Celgene Corporation (NASDAQ:CELG). Moreover, Patten Group has 0.35% invested in Celgene Corporation (NASDAQ:CELG). Mirae Asset Invests holds 74,304 shs. Shelton Capital Mngmt holds 0.62% of its capital in Celgene Corporation (NASDAQ:CELG) for 91,918 shs. Westover Cap Advisors Limited Liability has invested 1.03% in Celgene Corporation (NASDAQ:CELG). Philadelphia Trust reported 1.51% stake. Zwj Inv Counsel has 1.74% invested in Celgene Corporation (NASDAQ:CELG). Advent Capital Mgmt De invested in 40,000 shs or 0.08% of the stock.

Celgene Corporation registered $3.58 million net activity with 1 buy and 3 insider sales since February 8, 2018. On Monday, March 12 LOUGHLIN JAMES J sold $851,093 worth of Celgene Corporation (NASDAQ:CELG) or 9,250 shs. On Thursday, February 15 KAPLAN GILLA had sold 18,500 shs worth $1.77M. Shares for $1.26 million were sold by MARIO ERNEST on Friday, February 23.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

A total of 20 analysts rate Celgene (NASDAQ:CELG) as follows: 13 “Buy”, 7 “Hold” and 0 “Sell”. Тherefore 65% are bullish. The firm has $152.0 highest and $90 lowest target. The avg target $122 is 49.95% above the last ($81.36) price. (NASDAQ:CELG) has 35 ratings reports on 17 May 2018 according to StockzIntelligence. On Monday, February 5 the rating was maintained by Mizuho with “Buy”. On Tuesday, February 13 Barclays Capital upgraded Celgene Corporation (NASDAQ:CELG) rating. Barclays Capital has “Buy” rating and $105.0 target. On Friday, January 5 the firm has “Hold” rating by Bank of America given. On Wednesday, February 28 the company was maintained by Stifel Nicolaus. On Wednesday, February 28 the firm has “Hold” rating given by Robert W. Baird. On Wednesday, April 4 the company was maintained by RBC Capital Markets. On Friday, December 22 the rating was maintained by SunTrust with “Buy”. In Monday, January 8 report Credit Suisse maintained the stock with “Buy” rating. On Wednesday, February 28 SunTrust downgraded the shares of CELG in report to “Hold” rating. On Thursday, January 25 the firm has “Buy” rating given by Guggenheim.

For more Celgene Corporation (NASDAQ:CELG) news released briefly go to: Seekingalpha.com, Prnewswire.com, Seekingalpha.com, Seekingalpha.com or Fool.com. The titles are as follows: “Celgene’s (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)” released on May 16, 2018, “Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead …” on May 16, 2018, “Celgene And Otezla Are Cracking” with a publish date: May 14, 2018, “Generic Revlimid Could Sink Celgene” and the last “Celgene Starts the Year With a Bang” with publication date: May 14, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: